Novo Nordisk A/S (NVO)vsTC Energy Corp (TRP)
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
TRP
TC Energy Corp
$64.08
+0.02%
ENERGY · Cap: $66.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 1928% more annual revenue ($309.06B vs $15.24B). NVO leads profitability with a 33.1% profit margin vs 23.1%. TRP appears more attractively valued with a PEG of 4.61. TRP earns a higher WallStSmart Score of 59/100 (C).
NVO
Buy55
out of 100
Grade: C
TRP
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Margin of Safety
-216.8%
Fair Value
$19.23
Current Price
$64.08
$44.85 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Strong operational efficiency at 45.4%
Large-cap with strong market position
Keeps 23 of every $100 in revenue as profit
16.5% revenue growth
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Moderate valuation
0.5% earnings growth
Expensive relative to growth rate
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bull Case : TRP
The strongest argument for TRP centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 23.1% and operating margin at 45.4%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : TRP
The primary concerns for TRP are P/E Ratio, EPS Growth, PEG Ratio. Debt-to-equity of 2.23 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVO profiles as a declining stock while TRP is a growth play — different risk/reward profiles.
TRP carries more volatility with a beta of 1.00 — expect wider price swings.
TRP is growing revenue faster at 16.5% — sustainability is the question.
TRP generates stronger free cash flow (548M), providing more financial flexibility.
Bottom Line
TRP scores higher overall (59/100 vs 55/100), backed by strong 23.1% margins and 16.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
TC Energy Corp
ENERGY · OIL & GAS MIDSTREAM · USA
TC Energy Corporation is an energy infrastructure company in North America. The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?